← Back to Clinical Trials
Recruiting NCT05718726

NCT05718726 Post Splenectomy Infections After Surgery for Peritoneal Malignancies (OPSI)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05718726
Status Recruiting
Phase
Sponsor Hampshire Hospitals NHS Foundation Trust
Condition Infection;Post Surg Procedure
Study Type OBSERVATIONAL
Enrollment 300 participants
Start Date 2021-03-25
Primary Completion 2026-02-01

Trial Parameters

Condition Infection;Post Surg Procedure
Sponsor Hampshire Hospitals NHS Foundation Trust
Study Type OBSERVATIONAL
Phase N/A
Enrollment 300
Sex ALL
Min Age 18 Years
Max Age 79 Years
Start Date 2021-03-25
Completion 2026-02-01
Interventions
Questionnaire, interview or observation study

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The spleen is involved in maintaining immunity and plays an important role in the elimination of encapsulated bacteria and parasites. Patients who undergo splenectomy in conjunction with complete CRS for peritoneal malignancy are at risk of overwhelming post-splenectomy infections post-operatively. These patients are therefore administered vaccinations to lower the risk of infections but as they do not completely eliminate the risk, patients are also prescribed prophylactic antibiotics without clear evidence that they are useful in preventing OPSI. The use of prophylactic antibiotics is not without risk with potential short and long-term risks including resistance, interaction with other medication, clostridium difficile infections, fungal infections, other changes to the microbiome and cost. This study will investigate the incidence of OPSI post splenectomy and assess compliance with prophylactic antibiotics. This is an observational study where consented patients will be telephoned at fixed time points which are 1,6,12 weekly and 6 monthly for a period of five years post-operatively. As part of routine care patients will be telephoned by the clinical nurse specialist at weeks 1,6 and 12. In addition to this the research nurse will telephone the patient 6 monthly for a period of 5 years and complete a questionnaire. The research nurse will complete the questionnaire during each telephone call and this should not take more than 20 minutes. At the start of the telephone call, consent will be confirmed each time and the research nurse will check that the patient is still happy to participate before going ahead.

Eligibility Criteria

Inclusion Criteria: \- Patients aged \>18 and \<80 years Patients capable of providing informed consent Patients who have a splenectomy in conjunction with complete cytoreductive surgery (CRS) for any pathology Exclusion Criteria: \- Patients who are \<18 and \>80 Patients who do not provide informed consent Patients on immunosuppression therapy

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology